5 things to know about Gossamer Bio, a biotech with a surprisingly diverse pipeline

Gossamer Bio, Inc., a company with six drugs in its pipeline, is planing to go public and has applied to list on the Nasdaq exchange.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.